Moderna (MRNA) Receives a Buy from Brookline Capital Markets

Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna (MRNAResearch Report) today and set a price target of $506.00. The company’s shares closed last Wednesday at $188.47.

According to TipRanks.com, Cann is a 3-star analyst with an average return of 0.7% and a 43.0% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Syros Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moderna with a $216.55 average price target, representing a 29.1% upside. In a report issued on July 29, Goldman Sachs also reiterated a Buy rating on the stock with a $290.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Moderna’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.07 billion and net profit of $3.66 billion. In comparison, last year the company earned revenue of $1.94 billion and had a net profit of $1.22 billion.

Based on the recent corporate insider activity of 200 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRNA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Read More on MRNA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More